

Form PTO-1449 (modified)		Atty. Docket No. 4100.001000/DWH	Serial No. 09/389,435
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: 1643
U.S. Patent Documents See Page 1	Foreign Patent Documents	Other Art See Pages 1-9	

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	4,762,705	08/09/88	Rubin	424	85	03/29/84
	A2	5,057,302	10/15/91	Johnson <i>et al.</i>	424	1.1	01/04/88
	A3	5,100,885	03/31/92	Abrams <i>et al.</i>	514	184	08/01/89
	A4	5,169,858	12/08/92	Rubin	514	365	02/26/86
	A5	5,385,933	01/31/95	Rabinovitz <i>et al.</i>	514	499	06/19/92
	A6	5,563,132	10/08/96	Bodaness	514	185	06/21/94

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Allen and Solomons, "Normal intestinal mechanisms in the absorption of copper," In: <i>Absorption and Malabsorption of Mineral Nutrients</i> , Solomons and Rosenberg, Eds., Alan R. Liss, Inc., New York, 12:199-229, 1984.
	C2	Alpern-Elran and Brem, "Angiogenesis in human brain tumors: inhibition by copper depletion," <i>Neurological Surgery</i> , pp. 498-500, publication date unknown. no date
	C3	Brem <i>et al.</i> , "Anticopper treatment inhibits pseudopodial protrusion and the invasive spread of 9L gliosarcoma cells in the rat brain," <i>Neurosurgery</i> , 26:391-396, 1990.

EXAMINER: /Leigh Maier/

DATE CONSIDERED: 05/30/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/

Form PTO-1449 (modified)	Atty. Docket No. 4100.001000/DWH	Serial No. 09/389,435
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
	Filing Date: September 3, 1999	Group: 1643
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents	Other Art <i>See Pages 1-9</i>

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C4	Brem <i>et al.</i> , "Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic colactor," <i>Am. J. Pathol.</i> , 137(5):1121-1142, 1990.
	C5	Brem <i>et al.</i> , "Tetrathiomolybdate, a chelator of copper, reduces intracerebral peritumoral edema in rats," <i>Proceeding of the American Association for Cancer Research</i> , 33:76, Abstract 455, 1992.
	C6	Bremner <i>et al.</i> , "Copper metabolism in rats given di-or trithiomolybdates," <i>J. Inorg. Biochem.</i> , 16: 109, 1982.
	C7	Brewer and Yuzbasiyan-Gurkan, "Wilson Disease," <i>Medicine</i> , 71(3):139-164, 1992.
	C8	Brewer and Yuzbasiyan-Gurkan, "Wilson's Disease," In: <i>Textbook of Clinical Neuropharmacology and Therapeutics</i> , 2nd Edition, Klawans <i>et al.</i> , Eds., Raven Press, New York, pp. 191-205, 1992.
	C9	Brewer and Yuzbasiyan-Gurkan, "Wilson's disease: an update, with emphasis on new approaches to treatment," <i>Dig. Dis.</i> , 7(4):178-193, 1989.
	C10	Brewer, "Interactions of zinc and molybdenm with copper in therapy of Wilson's disease," <i>Nutr.</i> , 11(1 Suppl):114-116, 1995.
	C11	Brewer, "Practical recommendations and new therapies for Wilson's disease," <i>Drugs</i> , 50(2):240-249, 1995.
	C12	Brewer, "Thiomolybdates in the treatment of Wilson's disease," <i>Arch. Neurol.</i> , 49: 132-133, 1992.
	C13	Brewer, "Zinc in the Treatment of Wilson's Disease," <i>Nutrition and the M.D.</i> 19(12): 1993.
	C14	Brewer <i>et al.</i> , "Treatment of Wilson's disease with ammonium tetrathiomolybdate. I Initial therapy in 17 neurologically affected patients," <i>Arch. Neurol.</i> , 51(6):545-554, 1994.

EXAMINER: /Leigh Maier/

DATE CONSIDERED: 05/30/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/

Form PTO-1449 (modified)		Atty. Docket No. 4100.001000/DWH	Serial No. 09/389,435
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: 1643
U.S. Patent Documents See Page 1	Foreign Patent Documents	Other Art See Pages 1-9	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C15	Brewer <i>et al.</i> , "Use of zinc acetate to treat copper toxicosis in dogs," <i>JAVMA</i> 201:564-568, 1992.
	C16	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with zinc XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis," <i>J. Lab. Clin. Med.</i> , 123:849-858, 1994.
	C17	Brewer <i>et al.</i> , "Initial therapy of Wilson's Disease patients with tetrathiomolybdate," <i>Arch. Neurol.</i> , 48(1):42-47, 1991.
	C18	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with zinc III. Prevention of reaccumulation of hepatic copper," <i>J. Lab. Clin. Med.</i> , 109:526-531, 1987.
	C19	Brewer <i>et al.</i> , "Oral zinc therapy for Wilson's disease," <i>Annals Int. Med.</i> , 99:314-320, 1983.
	C20	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with zinc: IV. Efficacy monitoring using urine and plasma copper," <i>Proc. Soc. Exper. Biol. Med.</i> , 184:446-455, 1987.
	C21	Brewer <i>et al.</i> , "Treatment of Wilson's disease with ammonium tetrathiomolybdate II. Initial therapy in 33 neurologically affected patients and follow-up on zinc therapy," <i>Arch. Neurol.</i> , 53:1017-1025, 1996.
	C22	Brewer <i>et al.</i> , "The use of <sup>64</sup> copper measurements to diagnose canine copper toxicosis," <i>J. Vet. Int. Med.</i> , 6:41-43, 1992.
	C23	Brewer <i>et al.</i> , "Worsening of neurological syndrome upon initial treatment of Wilson's Disease patients with penicillamine," <i>Arch. Neurol.</i> , 44:490-493, 1987.
	C24	Brewer <i>et al.</i> , "Development of neurologic symptoms in a patient with asymptomatic Wilson's disease treated with penicillamine," <i>Arch. Neurol.</i> , 51:304-305, 1994.

EXAMINER: /Leigh Maier/

DATE CONSIDERED: 05/30/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/

Form PTO-1449 (modified)		Atty. Docket No. 4100.001000/DWH	Serial No. 09/389,435
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: 1643
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents	Other Art <i>See Pages 1-9</i>	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C25	Brewer <i>et al.</i> , "Zinc therapy of Wilson's Disease VIII. Dose response studies," <i>J. Trace Elem. Exp. Med.</i> , 3:227-234, 1990.
	C26	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with zinc: IX. Response of serum lipids," <i>J. Lab. Clin. Med.</i> , 118:466-470, 1991.
	C27	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with zinc XI. Interaction with other anticopper agents," <i>J. Amer. Coll. Nut.</i> , 12(1):26-30, 1993.
	C28	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with zinc XII. Dose regimen requirements," <i>Amer. J. Med. Sci.</i> , 305: (4):199-202; 1993.
	C29	Brewer <i>et al.</i> , "Molecular genetics and zinc-copper interactions in human Wilson's Disease and canine copper toxicosis," In: <i>Essential and Toxic Trace Elements in Human Health and Disease: An Update</i> , Prasad, Ed., Allan R. Liss, New York, PCBR 380:129-145, 1993.
	C30	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with zinc VI. Initial treatment studies," <i>J. Lab. Clin. Med.</i> , 114: 633-638, 1989.
	C31	Brewer <i>et al.</i> , "Treatment of Wilson's Disease," <i>Sem. Neurol.</i> , 7:209-220, 1987.
	C32	Coucouvanis <i>et al.</i> , "An inorganic functional group approach to the systematic synthesis and reactivity studies of binuclear Mo/S and Mo/S/O complexes," <i>Polyhedron</i> , 8(13/14):1705-1716, 1989.
	C33	Coucouvanis <i>et al.</i> , "Dinuclear Fe-Mo-S complexes containing the Fe <sub>2</sub> Mo core. Syntheses, ground-state electronic structures, and crystal and molecular structures of the [(C <sub>6</sub> H <sub>5</sub> ) <sub>4</sub> P] <sub>2</sub> [(C <sub>6</sub> H <sub>5</sub> S) <sub>2</sub> Fe <sub>2</sub> MoS <sub>2</sub> ], [(C <sub>2</sub> H <sub>5</sub> ) <sub>4</sub> N] <sub>2</sub> [(C <sub>6</sub> H <sub>5</sub> S) <sub>2</sub> Fe <sub>2</sub> WS <sub>2</sub> ], and [(C <sub>6</sub> H <sub>5</sub> ) <sub>4</sub> P] <sub>2</sub> [(S) <sub>5</sub> FeS <sub>2</sub> MS <sub>2</sub> ] (M = Mo, W) complexes," <i>Inorg. Chem.</i> , 22:293-308, 1983.
	C34	Coucouvanis <i>et al.</i> , "Heterodinuclear Di-μ-sulfido bridged dimers containing iron and molybdenum or tungsten. Structures of (PhP) <sub>2</sub> (FeMS <sub>9</sub> ) complexes (M = Mo, W)," <i>J. Am. Chem. Soc.</i> , 102:1730-1732, 1980.

EXAMINER: /Leigh Maier/

DATE CONSIDERED: 05/30/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/

Form PTO-1449 (modified)		Atty. Docket No. 4100.001000/DWH	Serial No. 09/389,435
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: 1643
U.S. Patent Documents See Page 1	Foreign Patent Documents	Other Art See Pages 1-9	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C35	Coucouvanis <i>et al.</i> , "Successful isolation of a reduced tetrathiomallate complex. Synthesis and structural characterization of the $[(\text{MoS}_4)_2\text{Fe}]^{3-}$ trianion," <i>J. Am. Chem. Soc.</i> , 102:6644-6646, 1980.
	C36	Coucouvanis <i>et al.</i> , "Synthesis and structural characterization of $[(\text{No})_2\text{FeS}_2\text{MoS}_2]^{2-}$ a dinitrosyl complex containing the $\text{FeS}_2\text{MoS}_2$ core," <i>Inorg. Chim. Acta</i> , 53:L135-L137, 1981.
	C37	Coucouvanis <i>et al.</i> , "Synthesis of thiomolybdenyl complexes with $[\text{Mo}_2(\text{S})_2(\text{O})_2]^{2+}$ cores and substitutionally labile ligands. Crystal and molecular structure of the $[\text{Mo}_2\text{O}_2\text{S}_4(\text{DMF})_3]$ complex," <i>Inorg. Chem.</i> , 27:3272-3273, 1988.
	C38	Coucouvanis <i>et al.</i> , "Trinuclear Fe-M-S complexes containing a linear Fe-M-Fe array and a bridging $\text{S}_2\text{MS}_2$ unit. Electronic structures and crystal and molecular structures of the $[(\text{C}_6\text{H}_5)_4\text{P}]_2[\text{Cl}_2\text{FeS}_2\text{MS}_2\text{FeCl}_2]$ ( $\text{M} = \text{Mo}, \text{W}$ ) complexes," <i>Inorg. Chem.</i> , 23:741-749, 1984.
	C39	Coucouvanis, "Fe-M-S complexes derived from $\text{MS}_4^{2-}$ anions ( $\text{M} = \text{Mo}, \text{W}$ ) and their possible relevance as analogues for structural features in the Mo site of nitrogenase," <i>Acc. Chem. Res.</i> , 14:201-209, 1981.
	C40	Coucouvanis, "Syntheses, structures, and reactions of binary and tertiary thiomolybdate complexes containing the $(\text{O})\text{Mo}(\text{S}_x)$ and $(\text{S})\text{Mo}(\text{S}_x)$ functional groups ( $x = 1, 2, 4$ )," <i>Adv. Inorg. Chem.</i> , 45:1-73, 1998.
	C41	Engleka and Maciag, "Inactivation of human fibroblast growth factor-1 (FGF-1) activity by interaction with copper ions involves FGF-1 dimer formation induced by copper-catalyzed oxidation," <i>J. Biol. Chem.</i> , 267:11307-11315, 1994.
	C42	Fell <i>et al.</i> , "Gut Pathology of Rats Dosed with Tetrathiomolybdate," <i>J. Com. Pathol.</i> , 89:495, 1979.

EXAMINER: /Leigh Maier/

DATE CONSIDERED: 05/30/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/

Form PTO-1449 (modified)		Atty. Docket No. 4100.001000/DWH	Serial No. 09/389,435
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: 1643
U.S. Patent Documents See Page 1	Foreign Patent Documents	Other Art See Pages 1-9	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C43	Folkman, "Angiogenesis," <i>The Journal of Biological Chemistry</i> , 267(16):10931-10934, 1992.
	C44	Folkman and Klagsbrun, "Angiogenic factors," <i>Science</i> , 23:442-447, 1987.
	C45	Folkman, "Angiogenesis in cancer, vascular, rheumatoid and other disease," <i>Nature Med.</i> , 1:27-31, 1995.
	C46	Folkman, "The influence of angiogenesis research on management of patients with breast cancer," <i>Breast Cancer Res. Treat.</i> , 36(2):109-118, 1995.
	C47	Folkman, "Antiangiogenic therapy," In: <i>Cancer: Principles and Practice of Oncology</i> , Lippincott-Raven Publishers, pp. 3075-3085, 1997.
	C48	Gooneratne <i>et al.</i> , "An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep," <i>Br. J. Nutr.</i> , 46:469, 1981.
	C49	Gooneratne <i>et al.</i> , "Intravenous administration of thiomolybdate for the prevention and treatment of chronic copper poisoning in sheep," <i>Br. J. Nutr.</i> , 46:457, 1981.
	C50	Gross <i>et al.</i> , "Inhibition of basic fibroblast growth factor-induced angiogenesis and glioma tumor growth <i>in vivo</i> in copper depleted rats," <i>Proceedings of the American Association for Cancer Research</i> , 32:57, Abstract 338, 1991.
	C51	Gullino, "Considerations on the mechanism of the angiogenic response," <i>Anticancer Res.</i> , 6(2):153-158, 1986.
	C52	Hadjikyriacou and Coucouvanis, "New members of the $[\text{Mo}_2(\text{S})_n(\text{S}_2)_{6-n}]^{2-}$ series. Synthesis, structural characterization, and properties of the $[\text{Mo}_2\text{S}_9]^{2-}$ , $[\text{Mo}_2\text{S}_7]^{2-}$ and $[\text{Mo}_2\text{S}_6]^{2-}$ thioanions," <i>Inorg. Chem.</i> , 26:2400-2408, 1987.
	C53	Hill <i>et al.</i> , "Treatment of Wilson's Disease with Zinc II. Validation of Oral $^{64}\text{Cu}$ Uptake with Copper Balance," <i>Am. J. Med. Sci.</i> , 12:344, 1986.

EXAMINER: /Leigh Maier/

DATE CONSIDERED: 05/30/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/

Form PTO-1449 (modified)		Atty. Docket No. 4100.001000/DWH	Serial No. 09/389,435
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: 1643
U.S. Patent Documents See Page 1	Foreign Patent Documents	Other Art See Pages 1-9	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C54	Hill <i>et al.</i> , "Treatment of Wilson's disease with zinc, I: oral zinc therapy regimens," <i>Hepatology</i> , 7:522-528, 1987.
	C55	Hourani and Demopoulos, "Inhibition of S-91 mouse melanoma metastases and growth by D-penicillamine," <i>Laboratory Investigation</i> , 21(5):434-438, 1969.
	C56	Kanatzidis and Coucouvanis, "Structure of Bis(tetraethylammonium) tetrathiomolybdate(VI), $2C_8H_{20}N^+MoS_4^{2-}$ ," <i>Acta Cryst.</i> , C39:835-838, 1983.
	C57	Lee <i>et al.</i> , "The Treatment of Wilson's Disease with Zinc VII. Protection of the Liver for Copper Toxicity by Zinc Induced Metallothionein in a Rat Model," <i>J. Lab. Clin. Med.</i> , 114:639-645, 1989.
	C58	Marshall <i>et al.</i> , "Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer," <i>Clin. Cancer Res.</i> , 3:2347-2354, 1997.
	C59	Merajver <i>et al.</i> , "Copper depletion as an anti-angiogenic strategy in HER2-neu transgenic mice," <i>Proceedings of Special AACR Conference on Angiogenesis and Cancer</i> , Abstract #B-11, January 22-24, 1998.
	C60	Merajver, "Phase I study of tetrathiomolybdate in metastatic cancer," NIH Grant No. 5R03CA77122-02. no date
	C61	Mills <i>et al.</i> , "Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats," <i>J. Inorg. Biochem.</i> , 14:189, 1981.
	C62	Mills <i>et al.</i> , "Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate," <i>J. Inorg. Biochem.</i> , 14: 163, 1981.
	C63	Parke <i>et al.</i> , "Characterization and quantification of copper sulfate-induced vascularization of the rabbit cornea," <i>Am. J. Pathol.</i> , 130:173-178, 1988.
	C64	Patstone and Maher, "Copper and calcium binding motifs in the extracellular domains of fibroblast growth factor receptors," <i>J. Biol. Chem.</i> , 271:3343-3346, 1996.

EXAMINER:

/Leigh Maier/

DATE CONSIDERED:

05/30/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/

Form PTO-1449 (modified)		Atty. Docket No. 4100.001000/DWH	Serial No. 09/389,435
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: 1643
U.S. Patent Documents See Page 1	Foreign Patent Documents	Other Art See Pages 1-9	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C65	Raju <i>et al.</i> , Ceruloplasmin, copper Ions, and angiogenesis," <i>J. Natl. Cancer Inst.</i> , 69:1183-1188, 1982.
	C66	Schapira and Schapira, "Use of ceruloplasmin levels to monitor response to therapy and predict recurrence of breast cancer," <i>Breast Cancer Res Treat.</i> , 3:223-224, 1983.
	C67	Schuschke <i>et al.</i> , "Short-term dietary copper deficiency does not inhibit angiogenesis in tumours implanted in striated muscle," <i>Br. J. Cancer</i> , 66:1059-1064, 1992.
	C68	Shing, "Heparin-copper bioaffinity chromatography of fibroblast growth factors," <i>J. Biol. Chem.</i> , 263:9059-9062, 1988.
	C69	Teo <i>et al.</i> , "Mo, W, and Fe EXAFS of the $[\text{Cl}_2\text{FeS}_2\text{MS}_2\text{FeCl}_2]^{2-}$ (M = Mo, W) dianions. A comparison with the Mo EXAFS of nitrogenase," <i>J. Am. Chem. Soc.</i> , 105:5767-5770, 1983.
	C70	Yoshida <i>et al.</i> , "Copper chelation inhibits tumor angiogenesis in the experimental 9L gliosarcoma model," <i>Neurosurgery</i> , 37(2):287-292, 1995.
	C71	Yoshida <i>et al.</i> , "Suppression of 9L gliosarcoma growth by copper depletion with copper-deficient diet and D-penicillamine," <i>J. Neurooncol.</i> , 17(2):91-97, 1993.
	C72	Yuzbasiyan-Gurkan <i>et al.</i> , "Treatment of Wilson's Disease with Zinc V. Changes in Serum Levels of Lipase, Amylase and Alkaline Phosphatase in Wilson's Disease Patients," <i>J. Lab. Clin. Med.</i> , 114:520-526, 1989.
	C73	Yuzbasiyan-Gurkan <i>et al.</i> , "The Treatment of Wilson's Disease with Zinc X. Intestinal Metallothionein Induction," <i>J. Lab. Clin. Med.</i> , 120:380-386, 1992.
	C74	Zagzag, "The effects of copper depletion on intracerebral angiogenesis and growth of experimental brain tumors," <i>Dissertation Abstracts International</i> , 53(12B):6160, 1988.

EXAMINER: /Leigh Maier/

DATE CONSIDERED: 05/30/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/



Form PTO-1449 (modified)	Atty. Docket No. 4100.001000/DWH	Serial No. 09/389,435
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
	Filing Date: September 3, 1999	Group: 1643
U.S. Patent Documents See Page 1	Foreign Patent Documents	Other Art See Pages 1-9

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C75	Ziche <i>et al.</i> , "Role of Prostaglandin E <sub>1</sub> and Copper in Angiogenesis," <i>J. Natl. Cancer Inst.</i> , 69:475-482, 1982.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/

EXAMINER: /Leigh Maier/

DATE CONSIDERED: 05/30/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)	Atty. Docket No. 4100.001000	Serial No. 09/389,435
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
	Filing Date: September 3, 1999	Group: 1623
U.S. Patent Documents	Foreign Patent Documents	Other Art See Pages 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C76	Brem "Angiogenesis and cancer control: From concept to therapeutic trail," <i>Cancer Control</i> , 6(5):436-458, 1999.
	C77	Brewer and Merajver, "Treatment of metastatic cancer with the anticopper antiangiogenic drug tetrathiomolybdate," <i>J. Invest. Med.</i> , 47(7):223A, 1999.
	C78	Brewer <i>et al.</i> , "Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study," <i>Clin. Canc. Res.</i> , 6(1):1-10, 2000.
	C79	International Search Report dated July 4, 2000 (PCT/US99/20374; 4100.001010).
	C80	Merajver, "A Phase I study of oral tetrathiomolybdate (TM) as a decoppering and anti-angiogenesis agent for metastatic cancer," From the Internet at website <a href="http://www.cancer.med.umich.edu/cgi-bin/protocol/9708_701">http://www.cancer.med.umich.edu/cgi-bin/protocol/9708_701</a> , 1998.
	C81	Sergeant and Johnson, "Iron and copper requirements for proliferation and differentiation of a human promyelocytic leukemia cell line (HL-60)," <i>J. Cell. Physiol.</i> , 163:477-485, 1995.
	C82	Shah <i>et al.</i> , "Circular dichroism of carbohydrate-molybdate complexes," <i>Stud. Nat. Prod. Chem.</i> , 15:423-438, 1995.

EXAMINER: /Leigh Maier/

DATE CONSIDERED: 05/30/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001000	Serial No. 09/389,435
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: 1623
U.S. Patent Documents <i>See Pages 1</i>	Foreign Patent Documents <i>See Pages</i>	Other Art <i>See Pages</i>	

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A7	5,697,902	December 16, 1997	Goldenberg	604	49	
	A8	5,565,491	October 15, 1996	Schieven	514	492	
	A9	5,512,559	April 30, 1996	Skalkos <i>et al.</i>	514	185	
	A10	5,443,816	August 22, 1995	Zamora <i>et al.</i>	424	1.69	
	A11	5,391,547	February 21, 1995	Cole <i>et al.</i>	514	184	
	A12	4,952,607	August 28, 1990	Sorenson <i>et al.</i>	514	589	
	A13	4,766,226	August 23, 1988	Hill <i>et al.</i>	556	18	
	A14	4,678,667	July 7, 1987	Meares <i>et al.</i>	424	85	
	A15	RE 35,458	February 18, 1997	Azuara	556	116	

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER: /Leigh Maier/

DATE CONSIDERED: 05/30/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.